Affiliation: GlaxoSmithKline Research and Development
- Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteersGemma Matthys
GlaxoSmithKline, Research Triangle Park, North Carolina, USA
J Clin Pharmacol 51:301-8. 2011..Eltrombopag pharmacokinetics and platelet response were dose-dependent, and doses up to 200 mg/d were well tolerated, with safety profiles similar to placebo...
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistJulian M Jenkins
GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
Blood 109:4739-41. 2007..These observations indicate that eltrombopag is a once-daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging further studies in patients with thrombocytopenia...
- Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysisJulian Jenkins
Oncology Medicine Development Center, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA
Eur J Clin Pharmacol 66:67-76. 2010..Therefore the potential for eltrombopag to interact with cytochrome P450 activity was investigated...